BriaCell Therapeutics Corp.
BCTXL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001610820
No open-market purchases or sales by BriaCell Therapeutics Corp. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $2.53M in total; no superinvestor holds it.
Holders of 5% or more of BCTXL
Holders whose latest Schedule 13D or 13G filing reports 5% or more of BriaCell Therapeutics Corp., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of BriaCell Therapeutics Corp. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on BriaCell Therapeutics Corp., newest first.
No Schedule 13D or 13G filings on BriaCell Therapeutics Corp. are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell BriaCell Therapeutics Corp. shares.
No Form 144 notices for BriaCell Therapeutics Corp. are on file.